Election of Species Joseph K. McKane SPE, Art Unit 1626 April 27, 2004.

Slides:



Advertisements
Similar presentations
Technology Center 1600 Training on Writing Rejections Under 35 U.S.C. § 103.
Advertisements

Disclaimer: The information provided by the USPTO is meant as an educational resource only and should not be construed as legal advice or written law.
The Procedure for Amending the Application under § Presented by Margaret W. Stevens, Head Supervisory Legal Instruments Examiner ;
The Examination Process
Incorporation by Reference
USPTO Restriction Training Materials and Chapter 800 Revisions
FITF Overview and Tips on Responding to Prior Art Rejections Biotechnology/Chemical/Pharmaceutical Customer Partnership Meeting United States Patent and.
G & B Seminar 2006 Claim Drafting Ken Moore.
More on Restriction Practice Jim Housel SPE, Art Unit 1648 (703)
UNITED STATES PATENT AND TRADEMARK OFFICE A full transcript of this presentation can be found under the “Notes” Tab. Claim Interpretation: Broadest Reasonable.
Double Patenting Simplified
Chemical Non-Statutory Double Patenting Examples Daniel Sullivan SPE, Art Unit 1621.
Joseph K. McKane SPE, Art Unit U.S.C. 112, second paragraph Allows the public to determine exactly what the boundaries of the claimed inventions.
Julie Burke TC1600 QAS REJOINDER PRACTICE Julie Burke TC1600 QAS
1 35 USC 112, 1 st paragraph enablement Enablement Practice in TC 1600 Deborah Reynolds, SPE
The America Invents Act (AIA) - Rules and Implications of First to File, Prior Art, and Non-obviousness -
September 14, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December.
35 U.S.C. 112, Sixth Paragraph MPEP 2181 – 2186 Jean Witz Quality Assurance Specialist Technology Center 1600.
1 Principles in Restriction Practice TC 1600 Anthony Caputa TC Practice Specialist (571)
Enhanced First Action Interview (EFAI) Pilot Program Wendy Garber Tech Center Director, 2100 United States Patent & Trademark Office.
Accelerated Examination Bennett Celsa (TC 1600: QAS)
“REACH-THROUGH CLAIMS”
1 Biotechnology Partnership Meeting April 17, 2001 James Martinell Senior Level Examiner Technology Center 1600.
Determination of Obviousness Practice Under the Genus-Species Guidelines and In re Ochiai; In re Brouwer Sreeni Padmanabhan & James Wilson Supervisory.
Restriction Practice for Nucleic Acid Molecules Julie Burke QAS/PM
1 Single Nucleotide Polymorphisms (SNP) Gary Jones SPE, Technology Center 1600 (703)
Restriction Practice for Genus Claims Species Claims Linking Claims and Markush Claims Julie Burke QAS/PM TC1600.
Appellate Procedure and Petition Practice By: Michael A. Leonard II.
By Paul J. Lee. Disclaimer The opinions and views expressed in these materials are not necessarily those of DexCom and reflect only the personal views.
RESTRICTING BETWEEN PRODUCT and PROCESS INVENTIONS Bruce Campell Supervisory Patent Examiner Art Unit
Current and Future USPTO Practice RESTRICTION PRACTICES AT THE USPTO 1 © AIPLA 2015.
Full First Action Interview (FFAI) Pilot Program Wendy Garber Tech Center Director, 2100 United States Patent & Trademark Office.
December 8, Changes to Patent Fees Under the Consolidated Appropriations Act, 2005 (H.R. 4818)(upon enactment) and 35 U.S.C. 103(c) as Amended by.
1 AIPLA Biotech Committee Meeting Washington D.C., October 14, 2004 Anthony Caputa, Ph.D. Technology Center Practice Specialist TC 1600.
1 ANTICIPATION BY INHERENCY IN PRIOR ART James O. Wilson Supervisory Patent Examiner Technology Center 1600 USPTO (571)
Broadening the Scope of the Claims in Gene Therapy Applications Deborah Reynolds Detailee, TCPS
Notice of Proposed Rule Making Affecting Claims That Recite Alternatives 1 Robert Clarke, Director Office of Patent Legal Administration (571)
Restriction & Double Patenting Mojdeh Bahar, J.D., M.A., CLP Chief, Cancer Branch Office of Technology Transfer National Institutes of Health U.S. Department.
Like.com vs. Ugmode Prosecution history of patent *** CONFIDENTIAL *** Prepared by Ugmode, Inc.
To Restrict or Not To Restrict That Is The Question? Divided We Stand! Or Undivided We Stand!! By Joseph K. McKane SPE, Art Unit 1626.
1 Restriction Practice Updates Julie Burke TC1600 Quality Assurance Specialist
3/2/091 PCT Unity of Invention with Pharmaceutical and Chemical Examples Julie Burke TC1600 Quality Assurance Specialist
July 18, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December 10,
Appeals in patent examination and opposition in Germany Karin Friehe Judge, Federal Patent Court, Munich, Germany.
1 Rules of Practice Before the BPAI in Ex Parte Appeals 73 Fed. Reg (June 10, 2008) Effective December 10, Fed. Reg (June 10, 2008)
1 When is it NOT Appropriate to Restrict? Julie Burke TC1600 QAS
Claims and Continuations Final Rule Overview Briefing for Examiners 1.
Examining Claims for Compliance with 35 U.S.C. 112(a): Part II – Enablement Focus on Electrical/Mechanical and Computer/Software-related Claims August.
Claims and Continuations Final Rule 1 Joni Y. Chang Senior Legal Advisor Office of Patent Legal Administration (571) ,
FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice Julie Burke TC1600 Quality Assurance Specialist
UNITED STATES PATENT AND TRADEMARK OFFICE
Restriction Practice for Combinations and Subcombinations
Vector Claims in Gene Therapy Applications: In vivo vs. In vitro Utilities Deborah Reynolds SPE GAU
“The Squeeze” Art and Enablement Together Yvonne L. Eyler, SPE AU 1646.
1 Restriction Petition Survey; A Few Helpful Hints Julie Burke TC1600 Special Program Examiner
James Toupin – General Counsel February 1, Summary of Proposed Rule Changes to Continuations, Double Patenting, and Claims.
Anthony Caputa Quality Lead OPQA
Claims Proposed Rulemaking Main Purposes É Applicant Assistance to Improve Focus of Examination n Narrow scope of initial examination so the examiner is.
Reviewing Common Themes in Double Patenting James Wilson, SPE 1624 TC
January 25, Notice of Proposed Rule Making Proposed Changes to Practice for Continuing Applications, Requests for Continued Examination Practice,
Double Patenting Deborah Reynolds SPE Art Unit 1632 Detailee, TC1600 Practice Specialist
Bruce Kisliuk Group Director, Technology Center 1600.
1 FY08 Restriction Petition Update and Burden Julie Burke Quality Assurance Specialist Technology Center 1600.
Processes Which Employ Non-Obvious Products
Claims and Continuations Final Rule
Ram R. Shukla, Ph.D. SPE AU 1632 & 1634 Technology Center
Biotech/Chem/Pharm Customer Partnership Meeting, March 15, 2005
Claim drafting strategies when filing a European patent application or entering the European phase of a PCT-application Christof Keussen
Examination Practice in Applications Presenting “Reach-Through Claims”
Presentation transcript:

Election of Species Joseph K. McKane SPE, Art Unit 1626 April 27, 2004

Example of Broad claim Claim 1. A compound selected from the group consisting of:

Markush definitions wherein: p is an integer ranging from 1 to 8; A is selected from O, S, and NR wherein R may be H or loweralkyl; X’, X”, X3, X4, X5, X6, R1 and R2 are independently selected and each represented by loweralkyl, loweralkoxy, alkoxyalkyl, hydroxyalkyl, aminoalkyl, alkylamino, alkylaminoalkyl, cycloalkyl, aryl, alkylaryl, halogen or: cycloalkyl, aryl, and alkylaryl and X1 and X2 are independently selected from H, loweralkyl, or loweralkoxy and the pharmaceutically acceptable salt thereof.

Species claims Claim 2. The compound according to claim 1, wherein said compound is represented by the formula: Claim 3. The compound according to claim 1, wherein said compound is represented by the formula: Claim 4. The compound according to claim 1, wherein said compound is represented by the formula:

Form Paragraph 8.01 Election of Species This application contains claims directed to the following patentably distinct species of the claimed invention: ***. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, *** generic.

8.01 Continued Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

8.01 Continued Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § (a).

8.01 Continued Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

8.02 Election when claims are not restricted to a species Claim*** generic to a plurality of disclosed patentably distinct species comprising ***. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

8.02 continued Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention. Note that this should be used in accordance with MPEP (Markush groups) and MPEP (d) (burdensome search).

Markush Claims/Species Election If the members of the Markush group are sufficiently few in number or so closely related that a search and examination of the entire claim can be made without serious burden, the examiner must examine all the members of the Markush group in the claim on the merits, even though they are directed to independent and distinct inventions.

Markush Claims/Species Election If on examination the elected species is found to be anticipated or rendered obvious, the Markush-type claims and claims to the elected species shall be rejected and claims to the non-elected species would be held withdrawn from further consideration. If there is no prior art that anticipates or renders obvious the elected species, the search of the Markush-type claim will be extended. If prior art is then found that anticipates or renders obvious the Markush-type claim with respect to a non-elected species, the Markush-type claim will be rejected and claims to the non- elected species held withdrawn from further consideration. The prior art search will not be extended unnecessarily to cover all non-elected species.

809.02(d) No Species Claims Where only generic claims are presented, no restriction can be required except in those applications where the generic claims recite such a multiplicity of species that an unduly extensive and burdensome search is necessary. See MPEP § (a). If after an action on only generic claims with no restriction requirement, applicant presents species claims to more than one species of the invention, he or she must at that time indicate an election of a single species.

Take Home Message When there is no prior art on a Markush- Type claim and/or elected species and the members of the Markush group are few in number and the species are closely related the examiner must extend the search to cover additional species and members of the Markush group.